487 related articles for article (PubMed ID: 34763205)
1. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.
Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A
EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205
[TBL] [Abstract][Full Text] [Related]
2. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
3. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.
Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
[TBL] [Abstract][Full Text] [Related]
5. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
8. Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine.
Chang YS; Huang K; Lee JM; Vagts CL; Ascoli C; Amin MR; Ghassemi M; Lora CM; Edafetanure-Ibeh R; Huang Y; Cherian RA; Sarup N; Warpecha SR; Hwang S; Goel R; Turturice BA; Schott C; Hernandez M; Chen Y; Jorgensen J; Wang W; Rasic M; Novak RM; Finn PW; Perkins DL
Elife; 2024 Apr; 13():. PubMed ID: 38656290
[TBL] [Abstract][Full Text] [Related]
9. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
10. Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
Du PX; Chang SS; Ho TS; Shih HC; Tsai PS; Syu GD
Virulence; 2024 Dec; 15(1):2351266. PubMed ID: 38717195
[No Abstract] [Full Text] [Related]
11. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
13. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.
Hod T; Ben-David A; Olmer L; Levy I; Ghinea R; Mor E; Lustig Y; Rahav G
Transplantation; 2021 Nov; 105(11):e234-e243. PubMed ID: 34310101
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
[TBL] [Abstract][Full Text] [Related]
15. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
16. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
[TBL] [Abstract][Full Text] [Related]
17. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ
Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762
[No Abstract] [Full Text] [Related]
18. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
Gilboa M; Mandelboim M; Indenbaum V; Lustig Y; Cohen C; Rahav G; Asraf K; Amit S; Jaber H; Nemet I; Kliker L; Bar-Haim E; Mendelson E; Doolman R; Rubin C; Regev-Yochay G; Kreiss Y
J Infect Dis; 2022 Mar; 225(5):785-792. PubMed ID: 34850049
[TBL] [Abstract][Full Text] [Related]
19. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
Peled Y; Ram E; Lavee J; Segev A; Matezki S; Wieder-Finesod A; Halperin R; Mandelboim M; Indenbaum V; Levy I; Sternik L; Raanani E; Afek A; Kreiss Y; Lustig Y; Rahav G
J Heart Lung Transplant; 2022 Feb; 41(2):148-157. PubMed ID: 34565682
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
Kumar D; Ferreira VH; Hall VG; Hu Q; Samson R; Ku T; Ierullo M; Majchrzak-Kita B; Tomlinson G; Gingras AC; Humar A
Ann Intern Med; 2022 Feb; 175(2):226-233. PubMed ID: 34807716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
